Reacting to a pharmaceutical company’s seemingly greedy ploy to jack up a premature birth-preventing drug from $10-$20 to $1,500 after the Food and Drug Administration granted it exclusive rights to produce the drug, the FDA shifted course and will allow specialty pharmacies into the market. [More]